As­traZeneca, Dai­ichi Sankyo tease new En­her­tu da­ta — but de­tails re­main un­der wraps

As­traZeneca and Dai­ichi Sankyo have new da­ta re­gard­ing their block­buster HER2-tar­get­ed ADC En­her­tu, but they won’t say ex­act­ly what’s com­ing down the pike.

The part­ners put out word Mon­day morn­ing that an analy­sis of a Phase II tri­al met a “pre­spec­i­fied tar­get for ob­jec­tive re­sponse rate and demon­strat­ed durable re­sponse” in dif­fer­ent types of ad­vanced, HER2-ex­press­ing sol­id tu­mors in pa­tients who had been heav­i­ly pre­treat­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER